: Net profit in 2025 is a loss of 199 million yuan.

Wanbangde released its performance report, with total operating income of 1.145 billion yuan in 2025, a year-on-year decrease of 20.69%. The net profit was a loss of 199 million yuan, compared to a net profit of 55.441 million yuan in the same period last year. The company was affected by the continuous advancement of national drug and medical device tendering and centralized procurement policies, the further expansion of the covered areas under centralized procurement, and a significant price decrease of the company's related products after centralized procurement. The industry market competition intensified, and some products failed to win bids in the tenth batch of national centralized procurement, resulting in a significant decrease in the company's profits.